Ehealth, Inc. dropped 21.01% intraday, with UBS adjusting its price target to $5 from $7, maintaining its rating. This adjustment, along with the company's second quarter 2025 financial results, likely contributed to the significant decline in the stock price.
Comments
No comments yet